Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: perakizumab, tibulizumab, m-1095 +8 | 0.90 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 2 stopped | 0.47 |
| literature PubMed | 54 Parkinson's papers of 13,758 | 0.47 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 2474
Sealed predictions
- IL17A in dopamine neurons, braak+0.43 (p 0.244) → +0.34 (p 0.371)receipt 2481
Swarm cases
receipt 2481: IL17A in dopamine neurons, braak
- power
- full sample +0.40 (p 0.099, n 18), 95% CI -0.08 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.099, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.41 (p 0.091, n 18). could be the mix.
- skeptic
- leave-one-out range +0.33 to +0.51, sign flips 0; without severely affected donors +0.40 (p 0.099, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IL17A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts